Albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine benefits patients with metastatic pancreatic cancer, according to the findings of a phase III study published in New England Journal of Medicine. Combined therapy significantly improved progression-free survival, overall survival and response rate compared with gemcitabine monotherapy. Grade 3 adverse events more frequent in the combined therapy group included neutropenia, fatigue and neuropathy.
References
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 10.1056/NEJMoa1304369
Rights and permissions
About this article
Cite this article
Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine. Nat Rev Gastroenterol Hepatol 10, 695 (2013). https://doi.org/10.1038/nrgastro.2013.223
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.223